Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | LTR Pharma Ltd (LTP.ASX) |
|---|---|
| Release Time | 29 Oct 2025, 8:51 a.m. |
| Price Sensitive | Yes |
Quarterly Activities and Appendix 4C Cash Flow Report
- ROXUS® development milestones achieved with stability testing progressing well, on track for US market launch H1 CY2026
- World-class US-based Scientific Advisory Board established to accelerate US market entry
- Peer-reviewed publication validates SPONTAN® delivers up to 5 times faster onset than oral tablets
LTR Pharma Limited (ASX:LTP) ('LTR Pharma' or 'the Company'), a company focused on improving men's health through clinical development and commercialisation of innovative nasal spray treatments for erectile dysfunction ('ED'), SPONTAN® and ROXUS®, is pleased to provide its Appendix 4C and an overview of its activities for the period ended 30 September 2025. The Company appointed two leading US erectile dysfunction specialists to its Scientific Advisory Board, substantially de-risking the planned H1 CY2026 ROXUS launch in the US$3.7 billion US market. LTR Pharma's Phase I pharmacokinetic data for SPONTAN were published in the peer-reviewed European Journal of Pharmaceutical Sciences, providing independent validation of SPONTAN's clinical differentiation. A four-patient case series presented at the 25th Asia-Pacific Prostate Cancer Conference demonstrated 100% patient satisfaction with SPONTAN in post-prostatectomy erectile dysfunction. SPONTAN achieved an 18-month shelf life under ICH stability conditions, confirming commercial-scale manufacturing capability. In September 2025, LTR Pharma secured a one-third ownership stake in LevOmega Pty Ltd at nil cost to shareholders, recognizing the Company's pharmaceutical development and commercialisation expertise. The Company maintained a strong financial position during the Quarter, with a cash balance of $29,733,623 as at 30 September 2025.
LTR Pharma is focused on executing key value-creating milestones, including commencing the SPONTAN Phase II pharmacokinetic study with patient enrolment in Q1 CY2026 and completing ROXUS development to enable launch in the US$3.7 billion US erectile dysfunction market in H1 CY2026.
The Company remains well-capitalised to execute its strategic priorities and is building substantial momentum towards transforming erectile dysfunction treatment globally.